Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas (ESPACE)
Liposarcoma, Atypical Lipomatous Tumor
About this trial
This is an interventional diagnostic trial for Liposarcoma focused on measuring Liposarcoma, Cancer, Atypical Lipomatous Tumor, New non-invasive biological test
Eligibility Criteria
Inclusion Criteria for LPS patients cohort:
Men/women older than 18 years old,
Surgery for :
- Localized WD-LPS and DD-LPS, and/or
- WD-LPS or DD-LPS local relapse, and/or
- WD-LPS or DD-LPS distant relapse and/or
- Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent
Inclusion Criteria for healthy subjects cohort:
Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort
Exclusion Criteria:
Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma.
Pregnancy and/or feeding
Sites / Locations
- Institut du Cancer de Montpellier - Val d'AurelleRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Healthy subjects cohort
Liposarcoma patients cohort
A single blood sample will be made in healthy subjects.
Blood samples will be collected at different times: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.